{"id":4179,"date":"2024-05-01T09:20:17","date_gmt":"2024-05-01T07:20:17","guid":{"rendered":"https:\/\/www.amyloidosisalliance.org\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/"},"modified":"2026-11-03T10:21:48","modified_gmt":"2026-11-03T09:21:48","slug":"se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina","status":"publish","type":"post","link":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/","title":{"rendered":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">El estudio publicado en Annals of Neurology, titulado \u00abDisease-Modifying Drugs Extend Survival in Hereditary Transthyretin Amyloid Polyneuropathy\u00bb, arroja luz sobre la eficacia de los tratamientos de la polineuropat\u00eda amiloide familiar (PAF). <br\/><br\/>La PAF, causada por mutaciones en el gen de la transtiretina, provoca la acumulaci\u00f3n de agregados de prote\u00ednas t\u00f3xicas en los tejidos nerviosos, con s\u00edntomas incapacitantes. No existe un tratamiento curativo, pero las opciones terap\u00e9uticas incluyen los f\u00e1rmacos modificadores de la enfermedad y el trasplante de h\u00edgado. <br\/><br\/>Los investigadores analizaron los datos de 201 pacientes con PAF a lo largo de tres d\u00e9cadas y observaron diferencias importantes de supervivencia entre los pacientes tratados y los no tratados.<br\/>Cabe destacar que se estim\u00f3 que casi todos los #pacientes tratados segu\u00edan vivos diez a\u00f1os despu\u00e9s del inicio de la enfermedad, frente a menos de la mitad de los pacientes no tratados. <br\/><br\/>Los f\u00e1rmacos modificadores de la enfermedad, como Onpattro, tafamidis y diflunisal, mostraron resultados prometedores en la supervivencia, con independencia de la edad de inicio de la enfermedad.<br\/>Incluso los pacientes con PAF de inicio tard\u00edo mejoraron su supervivencia con estos f\u00e1rmacos, lo que cuestiona la idea de que el trasplante de h\u00edgado era el tratamiento principal de las formas de inicio precoz. <br\/><br\/>Aunque el trasplante de h\u00edgado prolong\u00f3 la supervivencia en las formas de inicio precoz, su efecto en las formas de inicio tard\u00edo fue menos marcado.<br\/>El estudio subraya la importancia de los f\u00e1rmacos modificadores de la enfermedad para mejorar la supervivencia a largo plazo de los pacientes con PAF, con independencia de la edad de inicio o del tipo de s\u00edntomas. <br\/><br\/>No obstante, el an\u00e1lisis se limita a un solo centro, y se necesitan otros estudios para confirmar estos resultados en otras poblaciones y otros contextos m\u00e9dicos. <br\/><br\/>Consulte el art\u00edculo a continuaci\u00f3n <br\/><a href=\"https:\/\/urlr.me\/X1tHm\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-light-green-cyan-color\">https:\/\/urlr.me\/X1tHm<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.<\/p>\n","protected":false},"author":1,"featured_media":4180,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[52],"tags":[],"class_list":["post-4179","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-es"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina<\/title>\n<meta name=\"description\" content=\"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina\" \/>\n<meta property=\"og:description\" content=\"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/\" \/>\n<meta property=\"og:site_name\" content=\"Amyloidosis Alliance\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmyloidosisAlliance\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-01T07:20:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-03T09:21:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"880\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:site\" content=\"@amyloidosisa\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/\"},\"author\":{\"name\":\"Amyloidosis Alliance\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#organization\"},\"headline\":\"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina\",\"datePublished\":\"2024-05-01T07:20:17+00:00\",\"dateModified\":\"2026-11-03T09:21:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/\",\"name\":\"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"datePublished\":\"2024-05-01T07:20:17+00:00\",\"dateModified\":\"2026-11-03T09:21:48+00:00\",\"description\":\"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg\",\"width\":880,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/inicio\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/\",\"name\":\"Amyloidosis Alliance\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#organization\",\"name\":\"Amyloidosis Alliance\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/logo.png\",\"width\":252,\"height\":252,\"caption\":\"Amyloidosis Alliance\"},\"image\":{\"@id\":\"https:\\\/\\\/www.amyloidosisalliance.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmyloidosisAlliance\\\/\",\"https:\\\/\\\/x.com\\\/amyloidosisa\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina","description":"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/","og_locale":"es_ES","og_type":"article","og_title":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina","og_description":"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.","og_url":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/","og_site_name":"Amyloidosis Alliance","article_publisher":"https:\/\/www.facebook.com\/AmyloidosisAlliance\/","article_published_time":"2024-05-01T07:20:17+00:00","article_modified_time":"2026-11-03T09:21:48+00:00","og_image":[{"width":880,"height":500,"url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_creator":"@amyloidosisa","twitter_site":"@amyloidosisa","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#article","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/"},"author":{"name":"Amyloidosis Alliance","@id":"https:\/\/www.amyloidosisalliance.org\/es\/#organization"},"headline":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina","datePublished":"2024-05-01T07:20:17+00:00","dateModified":"2026-11-03T09:21:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/#organization"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/","url":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/","name":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina","isPartOf":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#primaryimage"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#primaryimage"},"thumbnailUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","datePublished":"2024-05-01T07:20:17+00:00","dateModified":"2026-11-03T09:21:48+00:00","description":"Un estudio realizado con 201 pacientes a lo largo de tres d\u00e9cadas sugiere que los tratamientos modificadores de la enfermedad prolongan la supervivencia en la amiloidosis ATTRv con polineuropat\u00eda.","breadcrumb":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#primaryimage","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/08\/Hereditary-Transthyretin-Amyloid-Polyneuropathy-.jpg","width":880,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/www.amyloidosisalliance.org\/es\/se-publica-un-nuevo-estudio-sobre-la-polineuropatia-amiloide-hereditaria-por-transtiretina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.amyloidosisalliance.org\/es\/inicio\/"},{"@type":"ListItem","position":2,"name":"Se publica un nuevo estudio sobre la polineuropat\u00eda amiloide hereditaria por transtiretina"}]},{"@type":"WebSite","@id":"https:\/\/www.amyloidosisalliance.org\/es\/#website","url":"https:\/\/www.amyloidosisalliance.org\/es\/","name":"Amyloidosis Alliance","description":"","publisher":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.amyloidosisalliance.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.amyloidosisalliance.org\/es\/#organization","name":"Amyloidosis Alliance","url":"https:\/\/www.amyloidosisalliance.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.amyloidosisalliance.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","contentUrl":"https:\/\/www.amyloidosisalliance.org\/wp-content\/uploads\/2026\/09\/logo.png","width":252,"height":252,"caption":"Amyloidosis Alliance"},"image":{"@id":"https:\/\/www.amyloidosisalliance.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmyloidosisAlliance\/","https:\/\/x.com\/amyloidosisa"]}]}},"_links":{"self":[{"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/posts\/4179","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/comments?post=4179"}],"version-history":[{"count":1,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/posts\/4179\/revisions"}],"predecessor-version":[{"id":4181,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/posts\/4179\/revisions\/4181"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/media\/4180"}],"wp:attachment":[{"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/media?parent=4179"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/categories?post=4179"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.amyloidosisalliance.org\/es\/wp-json\/wp\/v2\/tags?post=4179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}